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Objective: To estimate to what extent the mixture of ursolic acid and oleanolic acid, in
addition to the antitubercular standard regime, affects the hepatotoxicity proﬁle.
Methods: Liver injury was induced in male BALB/c mice by administering, per os and
daily for 11 weeks, a combination of anti-Tubercular (anti-TB) agents Rifampicin (10 mg/
kg), Isoniazid (10 mg/kg), and Pyrazinamide (30 mg/kg). The ursolic acid and oleanolic
acid mixture at doses of 100 or 200 mg/mouse/day was subcutaneously injected
throughout the entire study period (11 weeks). Biochemical and hematological analysis
was supplemented by liver histological examination.
Results: Animals treated with the mixture of triterpenic acids exhibited signiﬁcantly
decreased aspartate transaminase and alanine aminotransferase levels and amelioration of
the histopathological alterations produced by the anti-TB drugs.
Conclusions: The triterpene mixture was able to prevent the steatosis induced by the
anti-TB drugs.1. Introduction
Drug-induced liver toxicity is a serious potential adverse
effect produced by the currently used anti-Tubercular (anti-TB)
chemotherapeutic regimen containing Isoniazid (INH), Rifam-
picin (RIF) and Pyrazinamide (PZA). All of these anti-TB drugs
are potentially hepatotoxic, but when administered in combi-
nation, their toxic effects are enhanced in a synergistic manner
[1,2]. The precise mechanisms of INH and RIF hepatotoxicity are
not fully understood, but hepatocyte injury and death are most
likely due to toxic hydrazine derivatives and free radicals that
are responsible for oxidative stress, lipid peroxidation, and
choline deﬁciency, leading to the lowering of phospholipid
protein synthesis and the consequential alteration in cell wall
conﬁguration, reduced glutathione levels and the activation of
Cytochrome P450 2E1 (CYP2E1) [3,4].The conversion of monoacetyl hydrazine (AcHz), a metab-
olite of INH, into a toxic metabolite via cytochrome P450 leads to
hepatotoxicity. On the other hand, RIF promotes the cytochrome
P450 enzyme, increasing the production of toxic metabolites
from AcHz. The plasma half-life of AcHz is shortened and the
compound is quickly converted into its active metabolites.
Furthermore, RIF can increase the metabolism of INH to iso-
nicotinic acid, which is hepatotoxic. PZA is responsible for se-
vere hepatohypersensitivity reactions and, in combination with
INH and RIF, increases the incidence of hepatotoxicity [4–7].
The search for hepatoprotectors to prevent risk situations in
patients with tuberculosis (TB), who require treatment with anti-
TB is an issue of growing importance. The literature points to
the hepatoprotective effects of some synthetic compounds, such as
N-acetylcysteine [8], reamberine, remaxol and ademethionine [9].
At the same time, a group of naturally occurring compounds has
been reported as potential hepatoprotective agents against the
toxic effects of anti-TB, with the effects of silymarin [10–12],
curcumin and resveratrol [12–14], observed as remarkable. The
search for hepatoprotective agents that avoid antitubercular
drug-induced damage is mandatory, and this is reﬂected in the
large number of medicinal plant extracts undergoing validation.
The list of the latter is extensive and among these Silybum
marianum, the well-researched plant for the treatment of liverrticle under the CC BY-NC-ND license (http://
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(silybin A and B, isosilybin A and B silybin and other minor
compounds) are found in the seed's extract, denominated sily-
marin, which possesses hepatoprotective effects against the toxic
action of RIF [15] and which has been proposed as a dietary
supplement for patients treated with anti-TB [11]. In a
randomized, controlled clinical trial, Curcuma longa and
Tinospora cordiﬂora, in addition to the standard anti-TB regime,
very signiﬁcantly prevented, in terms of incidence, the duration
and severity of hepatotoxic episodes in patients with TB [3]. Some
medicinal plants extracts are proposed as hepatoprotectors, such as
garlic (Allium sativum) [16] and the root extracts from Punica
granatum and Cassia auriculata [17,18], Cnidoscolus
chayamansa [19], Vitex negundo [20], Hibiscus vitifolius [21],
Pisonia aculeate [22], Mikania scandens [23], Moringa oleifera
[24], Asteracantha longifolia [25] and others [26].
With regard to the mixture of triterpenes ursolic acid or
oleanolic acid (UA/OA), the natural product-of-interest in the
on-going study, in vivo anti-TB activity was already demon-
strated in an experimental mouse model of progressive pulmo-
nary TB, and a signiﬁcant reduction of bacterial loads and
pneumonia with a higher expression of Interferon gamma (IFN-
g) and Tumor necrosis factor alpha (TNF-a) in the lungs was
described. The authors concluded that the antimicrobial activity
of the mixture is concomitant to an immune-stimulatory effect
[27].
The in vivo antitubercular activity of these natural com-
pounds has been patented [28] and the results obtained here
comprise a breakthrough in understanding the simultaneous
role of these triterpene acids as both anti-TB and hep-
atoprotective agents.
On continuing the study of these compounds that offer po-
tential as anti-TB drugs, the hepatoprotective effect was sub-
jected to evaluation in an experimental model of liver damage
induced with the commonly used anti-TB ﬁrst-line drugs RIF/
INH/PZA.2. Material and methods
2.1. Chemical compounds
The mixture of UA/OA was obtained by chemical fraction-
ation of the methanolic extract of Bouvardia ternifolia aerial
parts. The puriﬁcation procedure was performed following the
methodology described previously [29] and was structurally
characterized by mass spectra and protonic nuclear magnetic
resonance spectrometric data by comparison with those
previously reported by this author. The drugs INH, RIF, PZA,
ultra-pure olive oil and sodium carboxymethyl cellulose were
purchased from Sigma–Aldrich and the kits used for determi-
nation of blood chemistry parameters were purchased from
Randox Co.2.2. Animals' treatment
In the present study, male Balb/C mice weighing (25 ± 2) g
were used and were obtained from CMN-SXXI Bioterium,
Mexico City. The mice were maintained in pathogen-free
housing in plastic cages during a 7 d conditioning period prior
to the performance of the experiments, under laboratory condi-
tions [12 h/12 h light/dark cycles; temperature (25 ± 2) C;humidity 45%–55%], with rodent chow food and water ad
libitum. The experiments were performed following the Statutes
of the International Committee for the Care and Use of Labo-
ratory Animals and Mexican Ofﬁcial Norm (NOM-062-ZOO-
1999) revised in 2001. All experimental protocols complied with
the Animal Care Committee of the Hospital de Especialidades at
the CMN-SXXI, IMSS.
As was previously reported, subcutaneous (s.c.) administra-
tion of the UA/OA mixture in models of acute toxicity, median
Lethal dose (LD50) was >2 g/kg in mice and rats and sub-acute
toxicity (for 28 d) did not cause lethality or alterations in blood
chemistry parameters or to histological changes in liver and
kidney [29]. Taking this data into account, doses of 100 and
200 mg (s.c) were administered daily to the mice.
Hepatotoxic damage was induced with a combination of anti-
TB drugs composed of INH (10 mg/kg), RIF (10 mg/kg) and
PZA (30 mg/kg) dissolved in Isotonic saline solution (ISS),
which was intragastrically (i.g) administered daily for 11 weeks.
Doses of anti-TB drugs were the same as those reported for the
in vivo assay [27]. The UA/OA mixture was dissolved in ultra-
pure olive oil (Sigma) and was administered s.c. together with
the anti-TB drugs for 11 weeks. A special #2 cannula was uti-
lized to facilitate i.g. administration of anti-TB drugs. Assess-
ment of the hepatoprotective potential of UA/OA was guided by
the methodology reported in references 21 and 48, with some
modiﬁcations.
Healthy mice were randomly assigned to six groups of eight
animals each as follows: Group I (negative control) with vehicle
(ISS i.g. and ultra-pure olive oil s.c.); Group II (positive control)
were treated with anti-TB drugs (RIF/INH/PZA) administered
i.g. via; Groups III and IV received UA/OA in doses of 100 and
200 mg/mouse/day by s.c. via, respectively; Group V animals
were administered with anti-TB drugs and UA/OA at a dose of
100 mg/mouse/daily and Group VI received anti-TB drugs and
UA/OA at a dose of 200 mg/mouse/day.
During the experimental period, the animals were observed
for signs of morbidity and mortality. The weight of all mice was
recorded from day zero and every 7 d thereafter throughout the
experiment until week 11. Animals that died during the exper-
imental period were dissected and the organs were obtained,
weighed and observed macroscopically.
2.3. Hematology and serum biochemistry
After the last treatment, the animals were left to fast for 12 h
and blood samples were collected by means of retro-orbital sinus
puncture without the use of anesthesia. Tubes with EDTA were
used for hematological testing and without anticoagulant for
biochemical analysis. Hematological analysis was performed
using a Beckman Coulter Cell Counter and the following pa-
rameters were determined: Total Red blood cell count; Hemo-
globin, Hematocrit; Mean corpuscular volume; Mean
corpuscular hemoglobin concentration; Mean corpuscular he-
moglobin; Total platelet count, Total White blood cell count and
a white-cell differential study was also performed to evaluate
lymphocytes, segmented neutrophils, eosinophils, monocytes,
and basophils.
Biochemical parameters with the commercially RANDOX
kits were obtained with Selectra Analyser (Vitalab 2 model)
automated equipment. In accordance with the manufacturer's
instructions, the following parameters were determined: glucose;
creatinine; urea; the liver marker enzymes Serum glutamic
Figure 1. Effect of the UA/OA mixture on body weight gain in anti-TB-
induced hepatotoxicity mouse model.
Data are mean ± SEM. Bifactorial statistical ANOVA of repeated measures,
post hoc SNK test (P < 0.05); avs. Vehicles; bvs. Anti-TB; cvs. 100 mg UA/
OA; dvs. 200 mg UA/OA; evs anti-TB + 100 mg UA/OA; fvs. Anti-
TB + 200 mg UA/OA; Anti-TB (RIF, INH, PZA); n = 8.
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Serum glutamic pyruvic transaminase or Alanine aminotrans-
ferase (ALT) and Alkaline phosphatase (ALP).
2.4. Histopathological evaluation
The mice were sacriﬁced by cervical dislocation and nec-
ropsy was carried out soon after death for macroscopic exami-
nation of liver, kidneys and spleen. Tissue biopsies from these
organs were ﬁxed in 10% formalin, processed and embedded in
parafﬁn. The parafﬁn block was cut into (4–5) mm slices with a
rotary microtome and stained with Hematoxylin and Eosin
(H&E), following the procedure described previously in 27. The
samples were examined under a light microscope with particular
attention paid to organs exhibiting: microscopic ﬁndings in liver
such as steatosis, necrosis, microabscesses, ﬁbrosis, portal lin-
foide inﬂammation and centrolobulillar hydropic degeneration;
in spleen was hematopoiesis and kidney tubular necrosis and
hydropic tubular changes.
2.5. Statistical analysis
SigmaPlot ver. 12.0 software (2011–2012) was employed for
analysis of results and graphic elaboration. Data are presented as
mean and Standard error of the mean ± SEM. Values of body
weight (BW) gain values were submitted to a bifactorial Anal-
ysis of variance (ANOVA) and to a post hoc Student–Newman–
Keuls (SNK) test. Results of P < 0.05 were considered signiﬁ-
cant. For hematological and biochemical data analysis, one-way
ANOVA was employed with a post hoc SNK test, in which
P < 0.05 was considered signiﬁcant. Finally, relative organ
weights in treated mice and Hematocrit data and the Kruskal–
Wallis test (ANOVA on ranks) were carried out with a post hoc
SNK test, in which relevant outcomes were those with a value of
P < 0.05.
3. Results
3.1. Body weight of the animals
In the course of 11 experimental weeks, a gradual increase in
BW gain in all groups was observed from day 28; however, up
the end of the study and in animals treated with the anti-TB
(Group II), this parameter was signiﬁcantly lower than that
presented by the remaining groups, determining one half of
those values registered for control group animals, which
received only the vehicle (3.54 g vs. 6.00 g). BW gain in Groups
III and IV mice, which were injected with UA/OA in 100 and
200 mg doses, exhibited behavior close to that of the control
group animals. With respect to Group V and VI mice treated
with UA/OA at 100 and 200 mg doses in addition to anti-TB
drugs, BW gain with the 200 mg dose demonstrated slightly
lower values than the controls (6.08 g), although at the end of
the study, BW gain was close to that of the control group (6.33
and 5.95 g, respectively) (Figure 1).Figure 2. Effect of the UA/OA mixture on % relative weight in anti-TB-
induced hepatotoxicity mouse model.
Data are mean ± SEM. Statistical analysis, Kruskal–Wallis test, ANOVA,
on ranks, post hoc SNK test (P < 0.05); avs. Vehicles; bvs. Anti-TB; cvs.
100 mg UA/OA; dvs. 200 mg UA/OA; evs. Anti-TB + 100 mg UA/OA; fvs.
Anti-TB + 200 mg UA/OA; Anti-TB (RIF, INH, PZA); n = 8.3.2. Relative organ weights
Signiﬁcant differences in the percentage of organ weight/BW
ratios were found only in the case of liver; therefore, we refer to
the particular case of this organ. Compared with the controlgroup (relative liver weight, 4.05%), an increase to 4.78% was
calculated for the group treated with anti-TB drugs. Relative
liver weights in mice treated only with 100 or 200 mg UA/OA
were similar to those of the control groups (4.06% and 4.12%,
respectively). Mice treated with anti-TB drugs in addition to
100 mg UA/OA exhibited a relative liver weight of 4.12%,
similar to that of the control group; in contrast, a different
behavior was observed when the dose of UA/OA to 200 mg. In
this latter case, relative liver weight increased to 4.74%, a value
similar to that of the group administered anti-TB drugs only
(Figure 2).
3.3. Hematological and biochemical parameters
Hematological parameters fell within the range of those
determined for control mice and mean values among groups
Figure 4. Effect of UA/OA mixture on serum AST concentration in anti-
TB-induced hepatotoxicity mouse model.
Data are mean ± SEM. Statistical analysis, one-way ANOVA post hoc SNK
test (P < 0.05); avs. Vehicles; bvs. Anti-TB; cvs. 100 mg UA/OA; dvs.
200 mg UA/OA; evs. Anti-TB + 100 mg UA/OA; fvs. Anti-TB + 200 mg UA/
OA; Anti-TB (RIF, INH, PZA); n = 8.
Figure 5. Effect of UA/OA mixture on serum ALT concentration in anti-
TB-induced hepatotoxicity mouse model.
Data are mean ± SEM. Statistical analysis, one-way ANOVA, post hoc
SNK test (P < 0.05); avs. Vehicles; bvs. Anti-TB; cvs. 100 mg UA/OA; dvs.
200 mg UA/OA; evs. Anti-TB + 100 mg UA/OA; fvs. Anti-TB + 200 mg UA/
OA; Anti-TB (RIF, INH, PZA); n = 8.
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evaluation of biochemical parameters, in none of the groups
tested were statistical differences established in serum glucose
and creatinine (parameters determining renal function), although
urea concentration in controls (62.140 ± 1.319) mg/dL increased
slightly (16.33%) in the anti-TB group (75.29 ± 2.19) mg/dL. In
contrast, urea levels in mice treated with both anti-TB and UA/
OA at the previously mentioned doses showed values of
(56.800 ± 1.151) mg/dL and (64.90 ± 2.06) mg/dL, respectively,
whereas the group treated only with UA/OA at 100 and 200 mg
doses, showing values of (65.51 ± 2.97) and (68.42 ± 1.86) mg/
dL respectively had plasma concentrations close to those of the
controls (Figure 3).
Transaminase values in the control group was AST
(155.91 ± 2.67) UI/L and ALP (45.27 ± 2.59) UI/L. Evaluation
of the liver function of the anti-TB group showed an increase in
both serum transaminase levels: AST (180.67 ± 3.85) UI/L and
ALT (86.33 ± 3.79) UI/L; this increase diminished signiﬁcantly
when the animals received anti-TB drugs and 100 mg of UA/OA
(AST 100.33 ± 2.86 UI/L; ALT 55.42 ± 4.25 UI/L), although the
group that received anti-TB plus 200 mg of UA/OA showed a
high values with respect to the control: AST (188.87 ± 1.87) UI/
L and ALT (98.00 ± 3.17) UI/L, these values were similar to
those of the anti-TB group. Results are illustrated in Figures 4
and 5. Furthermore, the serum concentration of ALP in the
anti-TB group showed the highest value with respect to negative
controls (182.33 vs. 161.09) UI/L. On comparison with the
controls, all treated groups of animals had higher ALP concen-
trations: UA/OA treatment at doses of 100 and 200 mg yielded
values of 174.67 and 177.91 UI/L, respectively, close to those of
the groups with UA/OA at 100 and 200 mg and the anti-TB
challenge (172.25 and 176.75) UI/L (Figure 6).
3.4. Histopathological analysis
The liver histological analysis revealed steatosis and
increased apoptosis only in the group submitted to anti-TB
drugs for 11 weeks (Figure 7A). Fatty accumulation was not
observed in the livers of control animals (Figure 7B), nor were
liver alterations detected in groups treated with 100 and 200 mg
UA/OA (Figure 7C), nor in animals receiving the anti-TBFigure 3. Effect of UA/OA mixture on serum urea concentration in anti-
TB-induced hepatotoxicity mouse model.
Data are mean ± SEM. Statistical analysis, one-way ANOVA, post hoc
SNK test (P < 0.05); avs. Vehicles; bvs. Anti-TB; cvs. 100 mg UA/OA; dvs.
200 mg UA/OA; evs. Anti-TB + 100 mg UA/OA; fvs. Anti-TB + 200 mg UA/
OA; Anti-TB (RIF, INH, PZA); n = 8.challenge in addition to 100 or 200 mg UA/OA (Figure 7D).
No changes in the kidney microscopic examination were iden-
tiﬁed. Splenic hematopoiesis was similar in mice with and
without treatment.Figure 6. Effect of UA/OA mixture on serum ALP concentration in anti-
TB-induced hepatotoxicity mouse model.
Data are mean ± SEM. Statistical analysis, one-way ANOVA, post hoc
SNK test (P < 0.05); avs. Vehicles; bvs. Anti-TB; cvs. 100 mg UA/OA; dvs.
200 mg UA/OA; evs. Anti-TB + 100 mg UA/OA; fvs. Anti-TB + 200 mg UA/
OA; Anti-TB (RIF, INH, PZA); n = 8.
Figure 7. Liver histology, mice groups with anti-TB (A), control (B), mixture of UA/OA at 100 mg/mice (C) and anti-TB plus mixture of UA/OA at
100 mg/mice (D).
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Evidences both in vitro and in vivo suggest that UA possesses
multi-fold biological properties, including anti-inﬂammatory,
anti-oxidative, hipolipidemic and a hepatic metallothionein-
inducer property, hepatoprotector effect, as well as other sig-
niﬁcant effects [29–32]. The same proﬁle can be noted regarding
OA, because this triterpene possesses promising
pharmacological activities, such as an anti-inﬂammatory agent,
an antioxidant, a cardioprotector, an antidiabetic and as a hep-
atoprotector [33–39].
Since the report of Jeong [39] concerning the protective effect
of OA against Carbon tetrachloride (CCl4)-induced
hepatotoxicity in mice, studies on the hepatoprotector effect of
both terpenoids against various drugs that induce
hepatotoxicity have appeared in the scientiﬁc literature.
Studies on in vivo experimental models have shown the effects
of OA and UA as protectors of acute liver injury induced by
CCl4, acetaminophen, paracetamol, ethanol and D-
galactosamine, being UA the most active drug [32,40–44].
Clinical trials in China showed that oral administration of OA
for 3 months or more in patients with acute and chronic liver
diseases decreased serum aminotransferase levels, symptoms
and the occurrence of cirrhosis in cases of patients with
chronic hepatitis [33,45].
The hepatoprotective effect of OA and UA against liver
damage induced by anti-TB drugs lengthens the list of the
multiple biological activities possessed by these triterpenes,
highlighting the already reported antimycobacterial activity and
antitubercular effect of the mixture [27,46]. The majority of endo-
and exo-genous substances are biotransformed in the liver and
when reactive products are generated, and they alter the
functional and structural integrity of the organ [4,5]. Drug use
is a major cause of hepatotoxicity and severe conditions such
as liver cirrhosis or hepatocellular carcinoma may occur, awell-known example comprising the hepatotoxicity caused by
anti-TB agents [13,19]. Hepatotoxic effects in anti-TB therapy
with ﬁrst-line agents are considered unique among liver prob-
lems because all these show dependence on the toxicity of the
drug used and the regime established [12,47].
The therapeutic value, efﬁcacy, and toxicity of drugs are
parameters that are evaluated as a ﬁrst step in animals with
experimentally induced liver damage. The animal model
employed in the present study induced hepatotoxicity in Balb/C
mice by means of anti-TB agents commonly used in humans, a
combination of RIF, INH and PZA [48]. It is well-known that
alterations in anti-TB-induced BW usually reﬂect physiolog-
ical changes in liver function. Throughout the experiment (11
weeks), the gradual increase of BW gain in mice treated with
anti-TB drugs was signiﬁcantly lower than those registered in
the other evaluated groups (a 58% reduction at the end of the
study). This behavior was not reproduced in mice treated with
anti-TB drugs plus 100 or 200 mg of UA/OA, meaning that the
triterpene mixture supported the normal growth of animals. On
the other hand, signiﬁcant differences in the relative organ
weights were found only in liver samples. In this case, the group
treated with anti-TB drugs showed a higher relative weight gain
(4.78%) with respect to that of the control group (4.05%), but
the parameter decreased when the anti-TB group in addition
received 100 mg UA/OA (4.12%); in contrast to this, a different
behavior was observed on increasing the UA/OA dose to
200 mg; in this case, the triterpene mixture did not act in the
same manner. In this regard, studies-in-progress are currently
being conducted to clarify this response.
High levels of urea are due to protein metabolism, which
takes place in the liver and normally occurs when hepatotoxicity
is induced [49,50]. A slight increase in urea levels was determined
in the anti-TB group, and administration of UA/OA (100 and
200 mg) returned this parameter to values close to those of the
control group, with the 100 mg concentration being the more
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being a serious adverse complication of anti-TB therapy, which
ranges from asymptomatic elevation of serum transaminases to
acute liver failure. First-line anti-TB drugs raise the levels of
hepatic enzymes AST and ALT and liver biopsies reveal lobular
hepatitis [4,19]. RIF is a powerful enzyme inducer that enhances
the hepatotoxicity of INH and PZA. Hepatotoxicity was detected
in 1%–2% of patients treated with this drug, and high values of
liver enzymes transaminases AST/ALT and ALP in plasma were
reported [19,52]. An augmented level of these hepatic markers in
serum may indicate cellular leakage and loss of functional
integrity of the cell membrane in liver as a result of the
oxygen free radicals produced by anti-TB drugs [7,53,54].
Our results after 11 treatment weeks assume the initiation of a
hepatotoxic process in the group of mice treated with anti-TB,
because serum transaminases AST and ALT were signiﬁcantly
increased. Administration of 100 mg UA/OA as a unique agent
produced an important decrease of AST concentration; an effect
of the same magnitude was detected in mice receiving anti-TB
drugs in addition to the triterpene mixture. The effect of UA/
OA on ALT concentrations was also appreciated, although with
less intensity.
Mice treated with anti-TB drugs initiated a steatosis process.
Histological liver analysis showed, in samples obtained from
animals administered the UA/OA mixture (100 or 200 mg) and
those treated with UA/OA plus the anti-TB challenge, a similar
architecture to that of the controls group. In the case of the anti-
TB-treated group, histological observations support the
biochemical ﬁndings, in that liver slides clearly depicted
morphological alteration related with fatty accumulation. From
this analysis, it is possible to support that treatment with the UA/
OA mixture was able to avoid hepatic lesions induced by RIF/
INH/PZA administration and nearly completely prevented the
development of liver steatosis. Evaluation of the UA/OA hep-
atoprotector effect in the experimental model described showed
that 100 mg offers better protection against damage caused by
anti-TB drugs.
While it is not possible to conclude, in this preliminary trial,
the underlying mechanism of the UA/OA hepatoprotector effect
against standard anti-TB drugs, we may assume the suppression
of Nuclear factor-kappa beta (NF-kB) activation, inhibition of
Cytochrome P450 2E1 (P4502E1) expression and activity, as
reported for the hepatoprotector effect of OA against CCl4 [39],
was enhanced hepatic-glutathione regeneration capacity [41], or
the upregulation of metallothionein expression mediated by
TNF-a and IL-6 shown in vitro [34,54], without dismissing the
background that these triterpenes possess as strong
antioxidants [55]. It is important to mention that additional
studies are underway to evaluate the hepatoprotector effects of
the triterpene mixture in this same model (Balb/c mice).
Animals were administered by oral via and with more
prolonged treatment periods (4 months). Another study
currently being developed is that of evaluating the
hepatoprotector effect of the triterpene (UA/OA) mixture are
administered by oral via but with higher doses of RIF/INH/
PZA (30, 30, and 90 mg/kg, respectively).
The results showed that UA/OA mixture was able to prevent
the steatosis induced by anti-TB drugs when was co-
administered daily during 77 d by s.c. The triterpene mixture
UA/OA favored BW gain and reduced levels of AST and ALT
in animals receiving anti-TB plus triterpenes. The animals
groups that only received triterpene mixture or vehicle didn'tshowed steatosis, and no alteration was observed on BW gain in
these groups. The values of AST, ALT and ALP were slightly
higher respect to vehicle group but lower than the group treated
with anti-TB drugs. We have previously shown that the mixture
of UA/OA has antitubercular activity and now we are demon-
strating that this mixture protects against damage caused by the
basic drugs to treat TB (RIF/INH/PZA).
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